Skip to content

OIS@SECO

MARCH 4, 2020 | ATLANTA, GA

The “Ophthalmic” Innovation Summit was introduced to facilitate meaningful interactions between ODs, MDs and Industry leaders to accelerate the adoption of innovative non-surgical therapies to address prevalent eye diseases and disorders.

OIS ISRAEL 2020

MARCH 18, 2020 | TEL AVIV, ISRAEL

Ophthalmology Innovation Summit is proud to announce our first international meeting in the beautiful city of Tel Aviv, Israel.

 

OIS ANTERIOR 2020

MAY 14, 2020 | CAMBRIDGE, MA

This Ophthalmology Innovation Summit unites over 600 Corporate, Clinical and Capital leaders to collaborate on the development and commercialization of innovative therapies for the anterior segment.

OIS RETINA 2020

JULY 23, 2020 | SEATTLE, WA

This Ophthalmology Innovation Summit unites 300 Corporate, Clinical and Capital leaders to collaborate on the development and commercialization of innovative therapies for the posterior segment.

12TH ANNUAL OIS 2020

NOVEMBER 12, 2020 | LAS VEGAS, NV

The Ophthalmology Innovation Summit began in 2009 and now unites over 1,200 Corporate, Clinical and Capital leaders to collaborate on the development and commercialization of innovative drugs, devices and diagnostics to address unmet vision disorders.

The Ophthalmology Innovation Summits facilitate meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.

LATEST NEWS

Keeping an "Eye on Innovation" Through News & Analysis

We’ve Got Your BAK

We’ve Got Your BAK

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would ...
OIS Index Outperforms

OIS Index Outperforms

The OIS Index of ophthalmic stocks gained 5.4% in November, following a similar 5.2% gain in October. The index outperformed medical device stocks (+4.3%) and ...
CorneaGen Aims to End Corneal Blindness

CorneaGen Aims to End Corneal Blindness

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has ...
RegenxBio sues FDA over clinical hold

RegenxBio sues FDA over clinical hold

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined ...
Bausch, Clearside See Gains Post-Deal

Bausch, Clearside See Gains Post-Deal

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a ...
OIS INDEX Oyster Point

Oyster Point Pharma Goes Public

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has ...

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.

Scroll To Top